{"id":8484,"date":"2022-03-29T13:02:05","date_gmt":"2022-03-29T13:02:05","guid":{"rendered":"https:\/\/live-cancer-factfinder.pantheonsite.io\/fact-finder-tool\/amyant\/"},"modified":"2026-10-20T17:10:35","modified_gmt":"2026-10-20T17:10:35","slug":"amyant","status":"publish","type":"post","link":"https:\/\/cancerfactfinder.org\/ht\/zouti-pou-cheche-enfomasyon\/amyant\/","title":{"rendered":"AFIKASYON: Amyant lak\u00f2z kans\u00e8"},"content":{"rendered":"\n

Sa ou ka tande<\/h2>\n\n

Ekspozisyon a amyant lak\u00f2z kans\u00e8. <\/span><\/p>\n\n

Sa syans di nou<\/h2>\n\n

Amyant te yon matery\u00e8l konstriksyon (yo te itilize li sitou nan izolasyon) epi yo ka jwenn li nan bilding ki te konstwi anvan ane 2000.<\/span> Ajans Ent\u00e8nasyonal pou Rech\u00e8ch sou Kans\u00e8 (IARC) klase amyant k\u00f2m yon kanseroj\u00e8n li te ye. Li lak\u00f2z kans\u00e8 l\u00e8 li sikatris tisi poumon an chak fwa ou respire fib li yo. De kalite kans\u00e8 ki pi komen ki lye av\u00e8k amyant se kans\u00e8 nan poumon ak mezotely\u00f2m (<\/span> ACS<\/span><\/a> ). Genyen tou yon lyen ant amyant ak to kans\u00e8 nan ov\u00e8 ak nan larenks.<\/span><\/p>\n\n

Pr\u00e8v Epidemyolojik<\/h3>\n\n

Plizy\u00e8 etid epidemyolojik montre ke ekspozisyon a amyant ogmante risk pou mezotely\u00f2m, yon kalite kans\u00e8 nan poumon. Yon etid ki te f\u00e8t nan Taiwan pami travay\u00e8 nan endistri pwosesis jad la te montre yon risk ogmante pou<\/span> kans\u00e8 nan poumon ( Lin et al.<\/a> )<\/span> . Yon l\u00f2t<\/span> etid kow\u00f2t ki baze sou popilasyon an<\/span> te jwenn tou ke moun k ap viv toupre izin fabrikasyon ki pwodui amyant te gen pi gwo pousantaj mezotely\u00f2m ak kans\u00e8 nan poumon konpare ak popilasyon jeneral la ( Zha et al.<\/a> ).<\/span> Etid kontw\u00f2l ka yo<\/span> te jwenn tou ke moun ki te ekspoze a amyant te gen yon risk ki pi wo pou yo devlope kans\u00e8 nan poumon ( Minowa et al.<\/a> ).<\/span><\/p>\n\n

Pr\u00e8v Laboratwa\/Pr\u00e8v Sip\u00f2<\/h3>\n\n

Plizy\u00e8 etid sou b\u00e8t yo montre ke ekspozisyon a amyant se danjere pou b\u00e8t yo epi li ka lak\u00f2z plizy\u00e8 kalite kans\u00e8, tankou mezotely\u00f2m. <\/span><\/p>\n\n

Klasifikasyon kanseroj\u00e8n IARC: <\/span><\/h3>\n\n

Gwoup 1 (Kanseroj\u00e8n pou moun)<\/span><\/p>\n\n

Kijan pou diminye risk ou<\/h2>\n\n

Depi k\u00f2mansman ane 2000 yo, anpil peyi ent\u00e8di itilizasyon amyant nan konstriksyon, epi yo f\u00e8 ef\u00f2 aktif pou retire amyant nan bilding ki te konstwi anvan 2000 tou, sitou Ozetazini ( ACS<\/a> ).<\/p>\n\n

Pou asire w ke ekspozisyon w a amyant pa tw\u00f2 wo, tcheke ki l\u00e8 yo te bati kay ou, kote w travay la, ak nenp\u00f2t l\u00f2t bilding ou abitye ye a. Si yo te bati nenp\u00f2t nan yo anvan ane 2000, tcheke pou w\u00e8 si yo te renove ak\/oswa enspekte pou amyant. Pif\u00f2 bilding yo te f\u00e8 sa, men si w pa s\u00e8ten, kontakte ACS la, paske se yo ki alat\u00e8t nan retire ak t\u00e8s amyant (NIOSH)<\/a> . <\/p>\n\n

Liy final la<\/h2>\n\n

Amyant se yon kanseroj\u00e8n byen koni, men pou pif\u00f2 moun, ekspozisyon a amyant pa yon enkyetid. Pou asire w ke ekspozisyon w lan ba, verifye ke kay ou ak espas travay ou satisf\u00e8 estanda nasyonal yo. <\/p>\n","protected":false},"excerpt":{"rendered":"

Sa ou ka tande Ekspozisyon a amyant lak\u00f2z kans\u00e8. Sa syans di nou Amyant te yon matery\u00e8l konstriksyon (yo te itilize li sitou nan izolasyon) epi yo ka jwenn li nan bilding ki te konstwi anvan ane 2000. Ajans Ent\u00e8nasyonal pou Rech\u00e8ch sou Kans\u00e8 (IARC) klase amyant k\u00f2m yon kanseroj\u00e8n li te ye. Li lak\u00f2z…<\/p>\n","protected":false},"author":1,"featured_media":8486,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[538],"tags":[472],"class_list":["post-8484","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-ekspozisyon-okipasyonel-ak-anviwonman","tag-definitivman-oswa-pwobableman-vre"],"acf":[],"_links":{"self":[{"href":"https:\/\/cancerfactfinder.org\/ht\/wp-json\/wp\/v2\/posts\/8484","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/cancerfactfinder.org\/ht\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/cancerfactfinder.org\/ht\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/cancerfactfinder.org\/ht\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/cancerfactfinder.org\/ht\/wp-json\/wp\/v2\/comments?post=8484"}],"version-history":[{"count":11,"href":"https:\/\/cancerfactfinder.org\/ht\/wp-json\/wp\/v2\/posts\/8484\/revisions"}],"predecessor-version":[{"id":18150,"href":"https:\/\/cancerfactfinder.org\/ht\/wp-json\/wp\/v2\/posts\/8484\/revisions\/18150"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/cancerfactfinder.org\/ht\/wp-json\/wp\/v2\/media\/8486"}],"wp:attachment":[{"href":"https:\/\/cancerfactfinder.org\/ht\/wp-json\/wp\/v2\/media?parent=8484"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/cancerfactfinder.org\/ht\/wp-json\/wp\/v2\/categories?post=8484"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/cancerfactfinder.org\/ht\/wp-json\/wp\/v2\/tags?post=8484"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}